The global blood stream infection testing market was valued at $10,540.8 million by 2030, and is anticipated to reach $5,173.1 million in 2021, growing at a CAGR of 8.3% from 2022 to 2030.
A blood stream infection is any bacterial, fungal, or other type of infection that is discovered in the blood. As soon as the infection enters the bloodstream of any part of the body, the illness becomes evident. . Testing for blood stream infections is done to find out which bacteria or other organisms are responsible for the blood infections. The ongoing population growth and worsening of sanitary conditions pose a serious threat to human health since they encourage the spread of various infectious illnesses. Due to the vast range of symptoms associated with bloodstream infections, including chills, cold, fever, diarrhea, and vomiting, self-diagnosis can be difficult. The BSI is concern for patient due to high morbidity and mortality rates. According to WHO It is estimated 49 million people and causes 11 million deaths globally every year. For detection and diagnosis of the infection, the in-vitro diagnostic techniques (blood cultures) are widely used. In the microbiology laboratory, technological developments in molecular approaches have transformed the approach of diagnosing microbial infections. As theses sophisticated technologies have become faster, more automated, and easier to use, they have become essential part of routine testing and repertoire in most diagnostic laboratories.
As technology develops and automated systems such as MALDI-TOF and DOT are developed, high cost of ownership and high maintenance expenses are projected to hinder the market growth. Also, costly testing techniques may make them unaffordable and this is projected to hamper the blood stream infection testing market trend. Market expansion can be constrained due to lack of insurance and reimbursement regulations.
The increase in the number of sepsis and bacteremia globally is expected to drive the blood stream infection testing market. Bacteremia and sepsis are few of the top causes of mortality rate in United States, causing over 600 fatalities each day. The need for rapid diagnosis and recent advancement in bloodstream infection testing are expected to boost the market growth. The increasing incidences of bloodstream infection in elderly population who are susceptible to infection due to low immunity is anticipate to drive the demand for blood stream infection testing market growth.
The COVID-19 epidemic in 2020 adversely affected the world's economy and triggered a public health calamity on a worldwide scale. However, the COVID-19 had a positive effect on the market for testing for blood stream infections worldwide.
Blood culture is the gold standard for identifying an illness or pathogen, thus in pandemic BSI testing has seen a sharp rise in popularity. The incidence rate of blood stream infection in COVID-19 patients was discovered to be 0.863% compared to patients without COVID having 0.437%. The rise in instances in North America and Europe accelerated the expansion of blood stream testing market. The need for infections or microorganisms to be diagnosed increased significantly.
The major key players in the global blood stream infection testing market are Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Abbott, BD, BIOMÉRIEUX, Cepheid, Luminex Corporation, Accelerate Diagnostics Inc., AdvanDX, and Bruker.
A blood stream infection is any bacterial, fungal, or other type of infection that is discovered in the blood. As soon as the infection enters the bloodstream of any part of the body, the illness becomes evident. . Testing for blood stream infections is done to find out which bacteria or other organisms are responsible for the blood infections. The ongoing population growth and worsening of sanitary conditions pose a serious threat to human health since they encourage the spread of various infectious illnesses. Due to the vast range of symptoms associated with bloodstream infections, including chills, cold, fever, diarrhea, and vomiting, self-diagnosis can be difficult. The BSI is concern for patient due to high morbidity and mortality rates. According to WHO It is estimated 49 million people and causes 11 million deaths globally every year. For detection and diagnosis of the infection, the in-vitro diagnostic techniques (blood cultures) are widely used. In the microbiology laboratory, technological developments in molecular approaches have transformed the approach of diagnosing microbial infections. As theses sophisticated technologies have become faster, more automated, and easier to use, they have become essential part of routine testing and repertoire in most diagnostic laboratories.
As technology develops and automated systems such as MALDI-TOF and DOT are developed, high cost of ownership and high maintenance expenses are projected to hinder the market growth. Also, costly testing techniques may make them unaffordable and this is projected to hamper the blood stream infection testing market trend. Market expansion can be constrained due to lack of insurance and reimbursement regulations.
The increase in the number of sepsis and bacteremia globally is expected to drive the blood stream infection testing market. Bacteremia and sepsis are few of the top causes of mortality rate in United States, causing over 600 fatalities each day. The need for rapid diagnosis and recent advancement in bloodstream infection testing are expected to boost the market growth. The increasing incidences of bloodstream infection in elderly population who are susceptible to infection due to low immunity is anticipate to drive the demand for blood stream infection testing market growth.
The COVID-19 epidemic in 2020 adversely affected the world's economy and triggered a public health calamity on a worldwide scale. However, the COVID-19 had a positive effect on the market for testing for blood stream infections worldwide.
Blood culture is the gold standard for identifying an illness or pathogen, thus in pandemic BSI testing has seen a sharp rise in popularity. The incidence rate of blood stream infection in COVID-19 patients was discovered to be 0.863% compared to patients without COVID having 0.437%. The rise in instances in North America and Europe accelerated the expansion of blood stream testing market. The need for infections or microorganisms to be diagnosed increased significantly.
The major key players in the global blood stream infection testing market are Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Abbott, BD, BIOMÉRIEUX, Cepheid, Luminex Corporation, Accelerate Diagnostics Inc., AdvanDX, and Bruker.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the blood stream infection testing market analysis from 2021 to 2030 to identify the prevailing blood stream infection testing market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the blood stream infection testing market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global blood stream infection testing market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
- By Product
- Instrument
- Consumables
- Software & Services
- By Technique
- Conventional
- Automated
- By technology
- Culture-based
- Molecular
- Proteomic
- By Application
- Bacterial
- Fungal
- Mycobacterial
- By End-user
- Hospitals
- Independent Diagnostics Centers
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- United Arab Emirates
- South Africa
- Rest of LAMEA
Key Market Segments
By Technology
- Culture-based
- Molecular
- Proteomic
By Product
- Instruments
- Consumables
- Software and Services
By Technique
- Conventional
- Automated
By Application
- Bacterial
- Fungal
- Mycobacterial
By End-users
- Hospitals
- Independent Diagnostics Centers
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- United Arab Emirates
- South Africa
- Rest of LAMEA
Key Market Players
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- becton dickinson medical devices co. ltd., suzhou
- bioMérieux SA
- cepheid
- Luminex Corporation
- Accelerate Diagnostics Inc.
- AdvanDx
- Bruker Corporation
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT
CHAPTER 5: BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE
CHAPTER 6: BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY
CHAPTER 7: BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION
CHAPTER 8: BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS
CHAPTER 9: BLOOD STREAM INFECTION TESTING MARKET, BY REGION
CHAPTER 10: COMPANY LANDSCAPE
CHAPTER 11: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report, titled, “Blood Stream Infection Testing Market," the bloodstream infection testing market size was $5.17 billion in 2021, and is estimated to reach $10.54 billion by 2030, growing at a CAGR of 8.3% from 2022 to 2030.Blood stream infection is a condition where any bacterial, fungal or any type of infection is detected in the blood. The condition is evident when the infection enters into the blood stream of any part of the body. The bacteria or organisms that causes the blood infection are determined by using blood stream infection testing. Increasing incidences of bloodstream infection in elderly population who are susceptible to infection due to low immunity is anticipated to drive the global bloodstream infection testing market demand and boost revenue growth of the market. The initiatives of various organizations to spread awareness regarding transfusion-transmitted infections is also expected to boost the market growth. High demand for technologically advanced diagnostic tests, awareness about hygiene, diagnosis rate, and unhealthy lifestyle are also expected to fuel the market growth over the forecast period.
However, absence of proper healthcare facilities related to medical testing, high diagnosis cost, and stringent regulatory situation acts as a hindrance to revenue growth of the market. The introduction of new cost-efficient and easy to use devices are projected to generate new opportunities for the major players within the forecast period.
According to the recent data by United Nations, as of July 2022, the global population has reached 7.96 billion. This rising population is predicted to fuel revenue growth of the blood stream infection testing market. According to the Centers for Disease Control and Prevention (CDC), patients with infections in the urinary tract, kidney, lung, and abdominal area are prone to suffer from Blood Stream Infection. In addition, people who are suffering with HIV or receiving chemotherapy treatment are at a higher risk of developing BSI. It is one of the serious complications for patients who are admitted in critical care units. This infection not only lengthens the hospital stay, but also increases chances of life-threatening comorbidities and sometimes leads to death.
The global bloodstream infection testing market is segmented based on product, technique, technology, application, end-user, and region. By product, the market is sub-segmented into instruments, consumables, and software & services. By technique, the market is sub-segmented into conventional and automated. By technology, the market is sub-segmented into culture-based, molecular, and proteomic. By application, the market is sub-segmented into bacterial, fungal, and mycobacterial. By end-user, the market is sub-segmented into hospitals, independent diagnostics centers, and others. By region, the market is sub-segmented into North America, Europe, Asia-Pacific, and LAMEA.
The major players in the global bloodstream infection testing market are Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Abbott, BD, BIOMÉRIEUX, Cepheid, Luminex Corporation, Accelerate Diagnostics Inc., AdvanDX, and Bruker.
The report offers a comprehensive analysis of the global bloodstream infection testing market trends by thoroughly studying different aspects of the market including major segments, market statistics, market dynamics, regional market outlook, investment opportunities, and top players working towards growth of the market. The report also sheds light on the present scenario and upcoming trends & developments that are contributing to the bloodstream infection testing market growth. Moreover, restraints and challenges that hold power to obstruct the bloodstream testing industry growth are also profiled in the report along with the Porter’s five forces analysis of the market to elucidate factors such as competitive landscape, bargaining power of buyers and suppliers, threats of new players, and emergence of substitutes in the market. These frameworks provide the complete Bloodstream Infection Testing Market Share.
Impact of Covid-19 on the Global Blood Stream Infection Testing Industry
- Businesses and economic activity around the world have been severely affected by the COVID-19 pandemic. Due to the low or non-existence of medical facilities/treatment centers, COVID-19 had a negative effect on the global bloodstream infection testing market
- Governments of various countries across the world were delaying or postponing unnecessary medical and surgical operations to relieve pressure on the healthcare system and minimize the spread of disease
- However, several market players developed a serology test/COVID-19 antibody test that uses a blood sample from the suspected individual. This started to increase the blood tests and also to cope the void created during the pandemic.
Key Findings of the Study
- Based on product, the consumables sub-segment is predicted hold the maximum market share and also to be the fastest growing sub-segment
- Based on technique, the conventional sub-segment is predicted to hold the maximum market share and the automated sub-segment is expected to grow with the highest CAGR over the forecast period
- Based on technology, the culture-based sub-segment is predicted to have a high market share throughout the analysis period and the molecular sub-segment is predicted to grow at the highest CAGR in the estimated timeframe
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Becton Dickinson Medical Devices Co. Ltd. Suzhou
- Biomérieux Sa
- Cepheid
- Luminex Corporation
- Accelerate Diagnostics Inc.
- Advandx
- Bruker Corporation
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
